Ketotifen effectively prevents mucosal damage in experimental colitis

R Eliakim ¹, F Karmeli , E Okon

⁰Department of Medicine, Hadassah University Hospital, Jerusalem, Israel.

Gut +

|

November 1, 1992

View abstract on PubMed

Summary

Ketotifen, a mast cell stabilizer, reduced inflammation and mucosal damage in experimental colitis models. This study suggests ketotifen

Area Of Science

Gastroenterology
Pharmacology
Inflammation Research

Background

Experimental colitis models are crucial for understanding inflammatory bowel disease (IBD).
Mast cell activation plays a significant role in the pathogenesis of colitis.

Purpose Of The Study

To investigate the therapeutic effects of ketotifen, a mast cell stabilizer, on experimental colitis.
To evaluate ketotifen's impact on inflammatory mediators and mucosal damage in colitis models.

Main Methods

Two models of experimental colitis were induced using trinitrobenzene sulphonic acid and acetic acid.
Ketotifen was administered intragastrically prophylactically and throughout the experimental period.
Measurements included mucosal damage, inflammatory mediator synthesis (PAF, PGE2, TXB2, LTB4, LTC4), and myeloperoxidase activity.

Main Results

Ketotifen significantly decreased mucosal damage in both colitis models.
A significant reduction in platelet-activating factor, prostaglandin E2, thromboxane B2, and leukotrienes C4 and B4 was observed.
Myeloperoxidase activity was reduced, particularly in the acetic acid model.

Conclusions

Ketotifen demonstrates potential in pharmacologically manipulating experimental colitis.
Further research is needed to elucidate ketotifen's mechanism of action and its clinical utility in inflammatory bowel disease.

Related Concept Videos